Histopathological and molecular analysis of gastrectomy specimens from hereditary diffuse gastric cancer patients has implications for endoscopic surveillance of individuals at risk

Journal of Pathology

Volumn 216, Issue 3, 2008, Pages 286-294

  Barber, M E ^a   Save, V ^b   Carneiro, F ^c   Dwerryhouse, S ^d   Lao Sirieix, P ^a   Hardwick, R H ^b   Caldas, C ^d,e   Fitzgerald, R C ^a  

^a HUTCHISON MRC RESEARCH CENTRE   (United Kingdom)

^b ADDENBROOKE S HOSPITAL   (United Kingdom)

^c UNIVERSITY OF PORTO   (Portugal)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^e CANCER RESEARCH UK CAMBRIDGE RESEARCH INSTITUTE   (United Kingdom)

Author keywords

CDH1; E cadherin; Epithelial mesenchymal transition; Gastrectomy; Hereditary diffuse gastric cancer; Prophylaxis; Surveillance

Indexed keywords

CYTOKERATIN 18; CYTOKERATIN 8; UVOMORULIN; VIMENTIN;

ADOLESCENT; ADULT; ARTICLE; CANCER RISK; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL PRACTICE; CONTROLLED STUDY; ENDOSCOPIC BIOPSY; FAMILIAL CANCER; FEMALE; GASTRECTOMY; GENE MUTATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; STOMACH CANCER; STOMACH MUCOSA;

ADULT; BIOPSY; CADHERINS; CARCINOMA, SIGNET RING CELL; CELL PROLIFERATION; FLUORESCENT ANTIBODY TECHNIQUE; GASTRIC MUCOSA; GASTROSCOPY; GENETIC PREDISPOSITION TO DISEASE; GERM-LINE MUTATION; HUMANS; IMMUNOHISTOCHEMISTRY; KERATIN-8; MALE; MIDDLE AGED; STOMACH NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; VIMENTIN;

EID: 55249127333     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.2415     Document Type: Article

References (29)

1. Caldas C, Carneiro F, Lynch HT, Yokota J, Wiesner GL, Powell SM, et al. Familial gastric cancer: overview and guidelines for management. J Med Genet 1999;36(12):873-880.
2. Park JG, Yang HK, Kim WH, Caldas C, Yokota J, Guilford PJ. Report on the first meeting of the International Collaborative Group on Hereditary Gastric Cancer. J Natl Cancer Inst 2000;92(21):1781-1782.
3. Brooks-Wilson AR, Kaurah P, Suriano G, Leach S, Senz J, Grehan N, et al. Germline E-cadherin mutations in hereditary diffuse gastric cancer: assessment of 42 new families and review of genetic screening criteria. J Med Genet 2004;41(7):508-517.
4. Oliveira C, Bordin MC, Grehan N, Huntsman D, Suriano G, Machado JC, et al. Screening E-cadherin in gastric cancer families reveals germline mutations only in hereditary diffuse gastric cancer kindred. Hum Mutat 2002;19(5):510-517.
5. Guilford P, Hopkins J, Harraway J, McLeod M, McLeod N, Harawira P, et al. E-cadherin germline mutations in familial gastric cancer. Nature 1998;392(6674):402-405.
6. Gayther SA, Gorringe KL, Ramus SJ, Huntsman D, Roviello F, Grehan N, et al. Identification of germ-line E-cadherin mutations in gastric cancer families of European origin. Cancer Res 1998;58(18):4086-4089.
7. Pharoah PD, Guilford P, Caldas C. Incidence of gastric cancer and breast cancer in CDH1 (E-cadherin) mutation carriers from hereditary diffuse gastric cancer families. Gastroenterology 2001;121(6):1348-1353.
8. Kaurah P, MacMillan A, Boyd N, Senz J, De Luca A, Chun N, et al. Founder and recurrent CDH1 mutations in families with hereditary diffuse gastric cancer. J Am Med Assoc 2007;297(21):2360-2372.
9. Chun YS, Lindor NM, Smyrk TC, Petersen BT, Burgart LJ, Guilford PJ, et al. Germline E-cadherin gene mutations: is prophylactic total gastrectomy indicated? Cancer 2001;92(1):181-187.
10. Norton JA, Ham VM, Dam JV, Jeffrey RB, Longacre TA, Huntsman DG, et al. CDH1 truncating mutations in the E-cadherin gene: an indication for total gastrectomy to treat hereditary diffuse gastric cancer. Ann Surg 2007;245(6):873-879.
11. Bradley EL III, Isaacs J, Hersh T, Davidson ED, Millikan W. Nutritional consequences of total gastrectomy. Ann Surg 1975;182(4):415-429.
12. Grady WM, Peek RM Jr. Hereditary diffuse gastric cancer: more answers or more questions? Gastroenterology 2002;122(3):830-831; discussion, 831-832.
13. Miholic J, Meyer HJ, Muller MJ, Weimann A, Pichlmayr R. Nutritional consequences of total gastrectomy: the relationship between mode of reconstruction, postprandial symptoms, and body composition. Surgery 1990;108(3):488-494.
14. Schwarz A. Preventive gastrectomy in patients with gastric cancer risk due to genetic alterations of the E-cadherin gene defect. Langenbecks Arch Surg 2003;388(1):27-32.
15. Fitzgerald RC, Caldas C. Clinical implications of E-cadherin-associated hereditary diffuse gastric cancer. Gut 2004;53(6):775-778.
16. Charlton A, Blair V, Shaw D, Parry S, Guilford P, Martin IG. Hereditary diffuse gastric cancer: predominance of multiple foci of signet ring cell carcinoma in distal stomach and transitional zone. Gut 2004;53(6):814-820.
17. Carneiro F, Huntsman DG, Smyrk TC, Owen DA, Seruca R, Pharoah P, et al. Model of the early development of diffuse gastric cancer in E-cadherin mutation carriers and its implications for patient screening. J Pathol 2004;203(2):681-687.
18. Roger WM, Dobo E, Norton JA, Van Dam J, Jeffrey BB, Huntsman DG, et al. Risk-reducing total gastrectomy for germline mutations in E-cadherin (CDH1): pathologic findings with clinical implications. Am J Surg Pathol 2008;(in press); DOI: 10.1097/PAS.0b013e31815e7f1a.
19. Humar B, Fukuzawa R, Blair V, Dunbier A, More H, Charlton A, et al. Destabilized adhesion in the gastric proliferative zone and c-Src kinase activation mark the development of early diffuse gastric cancer. Cancer Res 2007;67(6):2480-2489.
20. Lao-Sirieix P, Brais R, Lovat L, Coleman N, Fitzgerald RC. Cell cycle phase abnormalities do not account for disordered proliferation in Barrett's carcinogenesis. Neoplasia 2004;6(6):751-760.
21. Shaw D, Blair V, Framp A, Harawira P, McLeod M, Guilford P, et al. Chromoendoscopic surveillance in hereditary diffuse gastric cancer: an alternative to prophylactic gastrectomy? Gut 2005;54(4):461-468.
22. Gaya DR, Stuart RC, McKee RF, Going JJ, Davidson R, Stanley AJ. E-cadherin mutation-associated diffuse gastric adenocarcinoma: penetrance and non-penetrance. Eur J Gastroenterol Hepatol 2005;17(12):1425-1428.
23. Suriano G, Yew S, Ferreira P, Senz J, Kaurah P, Ford JM, et al. Characterization of a recurrent germ line mutation of the e-cadherin gene: implications for genetic testing and clinical management. Clin Cancer Res 2005;11(15):5401-5409.
24. Suriano G, Seixas S, Rocha J, Seruca R. A model to infer the pathogenic significance of CDH1 germline missense variants. J Mol Med 2006;84(12):1023-1031.
25. Blair V, Martin I, Shaw D, Winship I, Kerr D, Arnold J, et al. Hereditary diffuse gastric cancer: diagnosis and management. Clin Gastroenterol Hepatol 2006;4(3):262-275.
26. Francis WP, Rodrigues DM, Perez NE, Lonardo F, Weaver D, Webber JD. Prophylactic laparoscopic-assisted total gastrectomy for hereditary diffuse gastric cancer. JSLS 2007;11(1):142-147.
27. Huntsman DG, Carneiro F, Lewis FR, MacLeod PM, Hayashi A, Monaghan KG, et al. Early gastric cancer in young, asymptomatic carriers of germ-line E-cadherin mutations. N Engl J Med 2001;344(25):1904-1909.
28. Lewis FR, Mellinger JD, Hayashi A, Lorelli D, Monaghan KG, Carneiro F, et al. Prophylactic total gastrectomy for familial gastric cancer. Surgery 2001;130(4):612-617; discussion, 617-619.
29. 18F] Fluoro-2-deoxy-D-glucose positron emission tomography detects gastric carcinoma in an early stage in an asymptomatic E-cadherin mutation carrier. Clin Cancer Res 2004;10(19):6456-6459.